Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

$67.2M Next-Generation Antibiotic Contract Awarded

by Stephanie Lizotte
January 30, 2012
Drug Development for Biodefense

CUBRC, Inc. and Tetraphase Pharmaceuticals have been awarded a contract for the advanced development of an antibiotic (TP-434) that could potentially treat illnesses caused by biological threats such as anthrax, plague, bacterial pneumonia and certain life-threatening bacterial infections associated with prolonged hospitalization.

The Biomedical Advanced Research and Development Authority (BARDA) will support and manage the contract, which is worth $11.4 million in year one.  The contract can be extended to a total of five years, worth $67.2 million in the end.

TP-434 currently being developed by Tetraphase Pharmaceuticals is a tetracycline class of antibiotic, which treats intra-abdominal infections.  Early indications lead to the possibility that TP-434 could be effective against many antibiotic resistant bacteria.  The contract will support testing of TP-434 in clinical and animal studies and in improving drug manufacturing.  The development of both oral and intravenous formulations of TP-434 is supported.

TP-434 is the fourth to be funded under the Broad Spectrum Antimicrobials Program led by BARDA. Recognizing the critical linkage to national bioterrorist preparedness, the Pandemic and All Hazards Preparedness Act of 2006 specifically identifies BARDA’s role in the development of broad spectrum antimicrobials.

BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 available here.

Tags: AnthraxAntimicrobialsASPRAwardsBARDABioterrorismHHS

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC